A Phase 3, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Single Dose of Novartis Meningococcal ACWY Conjugate Vaccine, administered to Healthy Toddlers 12 Months of Age, Compared to Single Dose of Meningococcal C Conjugate Vaccine
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine group C conjugate
- Indications Meningococcal infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Novartis
- 30 Aug 2024 This trial has been completed in Czech Republic.
- 22 Oct 2013 New trial record